As previously reported, Scotiabank analyst Sung Ji Nam initiated coverage of Bionano Genomics with an Outperform rating and $4 price target. Bionano provides optical genome mapping technology tools and services to enable large-scale structural variation analysis of the genome, noted Ji Nam, who sees the company being "well positioned" to disrupt the cytogenetic testing market. He is projecting Bionano to deliver about 44% compound annual revenue growth over the next decade.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BNGO:
- Bionano Genomics to Host Strategy Day on February 2, 2023 in New York City
- Bionano Genomics sees FY22 revenue $27.7M-$28M, consensus $27.44M
- Bionano Genomics sees Q4 revenue of $8.1M-$8.4M, consensus $7.85M
- Bionano Genomics Reports Preliminary Fourth Quarter and Full-Year 2022 Results
- Bionano Genomics initiated with an Outperform at Scotiabank